Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25

Hi everyone,

Personally I was hoping of more than 20 successful recruitments, but I guess mgt advised that the remaining 25 will be completed by end of March 24.

the bit I liked in the quarterly was the following “…. No significant concerns have been noted to date, and no patients have withdrawn from the study. The earliest patients recruited have successfully transitioned into the open-label extension phase of the study, where they will receive an additional six months of treatment with ATL1102.”

So those first boys on the trial from Turkey are continuing to receive an additional 6 months of ALT1102. More over, no safety concerns and no withdrawals from the trial to date.

wish they could share some progressive data on the endpoint tests, but anyway the important thing is no safety concerns!! That will certainly help with any FDA discussions in the future

good luck to all.